SciSparc Initiates Clinical Trial in Tourette Syndrome

SciSparc Ltd (Nasdaq: SPRC) has initiated a Phase IIb Clinical Trial for its proprietary SCI-110 for the treatment of Tourette Syndrome (TS) at the Tel Aviv Sourasky Medical Center in Israel.

SciSparc’s Chief Executive Officer, Oz Adler, said, “TS in adults can be a debilitating disorder for which current treatments result in limited benefits. Encouraged by the results seen in the Phase IIa study at Yale School of Medicine, we look forward to continuing clinical research of the treatment regimen in this double-blind randomized trial.”


SciSparc’s clinical trial is based on positive data results received from the company’s single arm Yale School of Medicine study using SCI-110 for TS.

The trial will be conducted at three global leading centers of excellence: the Yale Child Study Center at the Yale School of Medicine in Connecticut, USA, the Hannover Medical School in Hannover, Germany, and at the Tel Aviv Sourasky Medical Center in Israel.

SciSparc has secured Institutional Review Board approvals from all three clinical sites.

The study will evaluate the efficacy, safety and tolerability of SciSparc’s proprietary drug candidate SCI-110 in adult patients (between 18 and 65 years of age) using a daily oral treatment.

The primary efficacy objective of the trial will be to assess tic severity change using the Yale Global Tic Severity Scale.

About SciSparc Ltd.

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds oil-based products on the Marketplace.

Share This Article


About the Author

SciSparc Initiates Clinical Trial in Tourette Syndrome

Editor Prism MarketView